Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr:33:100732.
doi: 10.1016/j.lanwpc.2023.100732. Epub 2023 Mar 7.

Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant

Matthew Zirui Tay  1 , Yun Shan Goh  1 , Siew-Wai Fong  1 , Zi Wei Chang  1 , Angeline Rouers  1 , Nathan Wong  1 , Anthony Torres-Ruesta  1 , Yuling Huang  1 , Sooriya Kannan Selvam  1 , Pei Xiang Hor  1 , Chiew Yee Loh  1 , Bei Wang  2 , Siti Nazihah Mohd Salleh  2 , Eve Zi Xian Ngoh  2 , Raphael Tze Chuen Lee  3   4 , Vanessa Neo  1 , Isaac Kai Jie Kam  1 , Xuan Ying Poh  5 , Suma Rao  5   6 , Po Ying Chia  5   6   7 , Sean W X Ong  5   6 , Tau Hong Lee  5   6 , Clarissa Lim  5 , Jefanie Teo  5 ; NCID Study Group; PRIBIVAC Cohort Study Group; Sebastian Maurer-Stroh  1   3   4   8   9   10 , Cheng-I Wang  2 , Yee-Sin Leo  5   6   7   11   12 , Raymond Tzer Pin Lin  5   8   13 , David C Lye  5   6   7   12 , Barnaby Edward Young  5   6   7 , Lisa F P Ng  1   14   15 , Laurent Renia  1   7   16
Affiliations

Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant

Matthew Zirui Tay et al. Lancet Reg Health West Pac. 2023 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

A patent application for the SFB assay has been filed (Singapore patent #10202009679P: A Method Of Detecting Antibodies And Related Products) by Y.S.G., L.R., and L.F.P.N. All other authors declare no competing interests.

Figures

Fig. 1
Fig. 1
(A) Anti-Spike IgG antibody binding responses were assessed in a cohort of 59 healthy individuals with no reported COVID-19 infection history who had received three doses of mRNA vaccines. Antibody responses against wild type (WT), Omicron BA.1 (BA1), and Omicron XBB (XBB) variants were assessed at the time of the third vaccine dose (day 1), as well as 28 days and 180 days subsequently. Bars and whiskers represent median values and interquartile range. Comparisons were made using Kruskal-Wallis test. (B) Pseudovirus neutralization IC50 values were assessed in a downselected group of 28 individuals from the same cohort. Bars and whiskers represent mean values and standard deviation. Comparisons were made using one-way ANOVA. (C) Anti-Spike IgG antibody responses of individuals who took the BNT162b2 monovalent vaccine for their third vaccine dose are plotted in red (n = 31), and mRNA-1273 monovalent vaccine in blue (n = 28). Bar represents the median value. (D) Pseudovirus neutralization IC50 values of individuals who took the BNT162b2 monovalent vaccine for their third vaccine dose are plotted in red (n = 15), and mRNA-1273 monovalent vaccine in blue (n = 13). IC50 = 50% inhibitory concentration. ∗P < 0.05. ∗∗P < 0.01. ∗∗∗P < 0.001. ∗∗∗∗P < 0.0001.
See this image and copyright information in PMC

References

    1. World Health Organization . 2022. Weekly epidemiological update on COVID-19-7 December 2022.https://www.who.int/publications/m/item/weekly-epidemiological-update-on...
    1. Focosi D., McConnell S., Casadevall A. The Omicron variant of concern: diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies. Drug Resist Updat. 2022;65:100882. - PMC - PubMed
    1. Goh Y.S., Ng L.F.P., Renia L. A flow cytometry-based assay for serological detection of anti-spike antibodies in COVID-19 patients. STAR Protoc. 2021;2(3):100671. - PMC - PubMed
    1. Poh C.M., Carissimo G., Wang B., et al. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nat Commun. 2020;11(1):2806. - PMC - PubMed
    1. Wang Q., Iketani S., Li Z., et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. bioRxiv. 2022 - PMC - PubMed

LinkOut - more resources